PPGN PolyPeptide Group AG
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About PolyPeptide Group (SWX: PPGN)
›
PolyPeptide Group (SWX: PPGN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,460 employees.
The shares were at 41.70 CHF on 19 November 2026, up 73.4% over 52 weeks. Its 52-week range is 21.80 CHF to 50.10 CHF: the price is 16.8% below the high and 91.3% above the low.
At a market capitalisation of 1.38B CHF, it trades at 101.7 times trailing earnings and 29.8 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 312% for PPGN.
PolyPeptide Group reports return on equity of -6.2%, an operating margin of 9.6% and revenue up 41.6% year over year.
Its debt exceeds its cash by 90.18M EUR, a debt-to-equity ratio of 0.38. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 5 analysts cover the stock; their mean price target of 42.89 CHF is 2.8% above the current price. The next earnings report is expected on 9 March 2027.